128 related articles for article (PubMed ID: 11888836)
1. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
[TBL] [Abstract][Full Text] [Related]
2. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
[TBL] [Abstract][Full Text] [Related]
3. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
Arvat E; Maccagno B; Ramunni J; Broglio F; Lanfranco F; Giordano R; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
[TBL] [Abstract][Full Text] [Related]
4. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
5. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
[TBL] [Abstract][Full Text] [Related]
7. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
Arvat E; Maccagno B; Ramunni J; Di Vito L; Gianotti L; Broglio F; Benso A; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
[TBL] [Abstract][Full Text] [Related]
8. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
[TBL] [Abstract][Full Text] [Related]
9. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
[TBL] [Abstract][Full Text] [Related]
10. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
[TBL] [Abstract][Full Text] [Related]
11. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
[TBL] [Abstract][Full Text] [Related]
12. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
15. Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.
Giusti M; Foppiani L; Ponzani P; Cuttica CM; Falivene MR; Valenti S
J Endocrinol Invest; 1997 May; 20(5):257-63. PubMed ID: 9258804
[TBL] [Abstract][Full Text] [Related]
16. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men.
Bergendahl M; Aloi JA; Iranmanesh A; Mulligan TM; Veldhuis JD
J Clin Endocrinol Metab; 1998 Jun; 83(6):1967-75. PubMed ID: 9626127
[TBL] [Abstract][Full Text] [Related]
17. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
Friend K; Iranmanesh A; Login IS; Veldhuis JD
Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
[TBL] [Abstract][Full Text] [Related]
18. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.
Ghigo E; Arvat E; Gianotti L; Grottoli S; Rizzi G; Ceda GP; Boghen MF; Deghenghi R; Camanni F
Eur J Endocrinol; 1996 Oct; 135(4):407-12. PubMed ID: 8921821
[TBL] [Abstract][Full Text] [Related]
19. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
[TBL] [Abstract][Full Text] [Related]
20. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
Korbonits M; Kaltsas G; Perry LA; Putignano P; Grossman AB; Besser GM; Trainer PJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2489-95. PubMed ID: 10404825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
